Kindai University researchers find arginine reduces Alzheimer's damage in animal models
Updated
Updated · ScienceDaily · May 4
Kindai University researchers find arginine reduces Alzheimer's damage in animal models
11 articles · Updated · ScienceDaily · May 4
In Osaka-led work published in Neurochemistry International, oral arginine cut amyloid plaque and insoluble Aβ42 in fly and App knock-in mouse models carrying familial Alzheimer's mutations.
Treated mice also performed better in behavioural tests, while gene activity linked to pro-inflammatory cytokines fell, suggesting reduced neuroinflammation alongside suppression of toxic Aβ42 aggregation.
Researchers say the inexpensive amino acid is already considered clinically safe, but stressed that human benefit, dosing and commercial supplement use still require further preclinical and clinical study.
If arginine is so common, why is its powerful effect on Alzheimer's only being discovered now?
A common supplement shows promise for Alzheimer's. Is the cure already on our shelves?
Affordable Amino Acid Arginine Offers Dual Action Against Alzheimer's: Amyloid Aggregation and Brain Inflammation
Overview
In late 2025, Kindai University researchers discovered that arginine, a safe and affordable amino acid, effectively reduces Alzheimer's disease pathology in animal models by directly inhibiting the aggregation of toxic Aβ42 peptides. This inhibition lowers amyloid plaque formation and decreases harmful brain inflammation, leading to improved behavior and survival in both fruit fly and mouse models. Arginine's excellent blood-brain barrier permeability and established safety profile support its potential for rapid clinical testing. Its dual action suggests the greatest benefit in early Alzheimer's stages and may extend to other neurodegenerative diseases, offering a promising, low-cost alternative to current expensive and less accessible antibody therapies.